Nyxoah price target lowered to $15 from $17 at H.C. Wainwright

H.C. Wainwright analyst Edward White lowered the firm’s price target on Nyxoah (NYXH) to $15 from $17 and keeps a Buy rating on the shares after the company announced that the FDA has issued an Approvable Letter regarding the Pre-Market Approval application for the Genio system to treat moderate-to-severe obstructive sleep apnea. The firm now expect a U.S. commercial launch of Genio to be delayed by six months into early 2026 following the news, the analyst tells investors.